Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

BACKGROUND: Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment. Adalimumab, a tumour necrosis factor (TNF)-alpha inhibitor, effectively controls joint and eye inflammation; however, its long-term use may i...

Descripción completa

Detalles Bibliográficos
Autores principales: Acharya, Nisha R., Ebert, Caleb D., Kelly, Nicole K., Porco, Travis C., Ramanan, Athimalaipet V., Arnold, Benjamin F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590716/
https://www.ncbi.nlm.nih.gov/pubmed/33109240
http://dx.doi.org/10.1186/s13063-020-04796-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590716/
https://www.ncbi.nlm.nih.gov/pubmed/33109240
http://dx.doi.org/10.1186/s13063-020-04796-z

Ejemplares similares